Literature DB >> 8177242

Inhibition of tumor necrosis factor-alpha by thalidomide in magnesium deficiency.

W B Weglicki1, R E Stafford, B F Dickens, I T Mak, M M Cassidy, T M Phillips.   

Abstract

The effect of thalidomide on circulating cytokines and myocardial lesion formation was investigated in Mg-deficient rats. After two weeks on a Mg-deficient diet, rats show an increase in circulating levels of tumor necrosis factor-alpha and interleukin 1. Thalidomide (1 mg/day) caused a complete inhibition of the increase in circulating tumor necrosis factor-alpha levels, without having an effect on interleukin 1. However, a marked increase in cardiomyopathic lesion formation was observed in Mg-deficient animals treated with thalidomide; possible mechanisms for thalidomide's enhancement of myocardial injury are discussed.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8177242     DOI： 10.1007/bf00926368

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN： 0300-8177            Impact factor:   3.396


  32 in total

1.  Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels.

Authors:  I T Mak; P Boehme; W B Weglicki
Journal:  Circ Res       Date:  1992-06       Impact factor: 17.367

Review 2.  Cytokines in disease.

Authors:  J T Whicher; S W Evans
Journal:  Clin Chem       Date:  1990-07       Impact factor: 8.327

3.  Tumor necrosis factor-alpha stimulates superoxide anion generation by perfused rat liver and Kupffer cells.

Authors:  A P Bautista; A Schuler; Z Spolarics; J J Spitzer
Journal:  Am J Physiol       Date:  1991-12

4.  Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Possible involvement of G proteins.

Authors:  P Braquet; D Hosford; P Koltz; J Guilbaud; M Paubert-Braquet
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

5.  Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin.

Authors:  W B Weglicki; T M Phillips; A M Freedman; M M Cassidy; B F Dickens
Journal:  Mol Cell Biochem       Date:  1992-03-25       Impact factor: 3.396

6.  Magnesium deficiency-induced cardiomyopathy: protection by vitamin E.

Authors:  A M Freedman; A H Atrakchi; M M Cassidy; W B Weglicki
Journal:  Biochem Biophys Res Commun       Date:  1990-08-16       Impact factor: 3.575

7.  Thalidomide for the treatment of chronic graft-versus-host disease.

Authors:  G B Vogelsang; E R Farmer; A D Hess; V Altamonte; W E Beschorner; D A Jabs; R L Corio; L S Levin; O M Colvin; J R Wingard
Journal:  N Engl J Med       Date:  1992-04-16       Impact factor: 91.245

8.  Expression of tumor necrosis factor in human acute cardiac rejection. An immunohistochemical and immunoblotting study.

Authors:  E Arbustini; M Grasso; M Diegoli; M Bramerio; A S Foglieni; M Albertario; L Martinelli; A Gavazzi; C Goggi; C Campana
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

9.  Treatment of refractory rheumatoid arthritis--the thalidomide experience.

Authors:  O Gutiérrez-Rodríguez; P Starusta-Bacal; O Gutiérrez-Montes
Journal:  J Rheumatol       Date:  1989-02       Impact factor: 4.666

10.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

Authors:  E P Sampaio; E N Sarno; R Galilly; Z A Cohn; G Kaplan
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307
View more
  2 in total

Review 1.  Thalidomide: rationale for renewed use in immunological disorders.

Authors:  U Schuler; G Ehninger
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

Review 2.  Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.

Authors:  Xiubao Chang; Yuanxiao Zhu; Changxin Shi; A Keith Stewart
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2013-12-29       Impact factor: 3.848
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.